Tauroursoursodeoxycholic acid, brand name tudcabil (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 97 | 潰瘍性大腸炎 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04114292 (ClinicalTrials.gov) | January 17, 2019 | 25/9/2019 | TUDCA as a Therapy for Ulcerative Colitis (UC) | A Phase I Open Label Study of the Efficacy and Safety of Tudca in Ulcerative Colitis | Ulcerative Colitis | Drug: Tauroursoursodeoxycholic acid, brand name Tudcabil | Washington University School of Medicine | Crohn's and Colitis Foundation | Recruiting | 18 Years | 65 Years | All | 13 | Phase 1 | United States |